PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery-Reference-Cited by-同舟云学术

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

Published:2011-09 Issue:9 Volume:22 Page:1988-1998
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Untch M.,Fasching P.A.,Konecny G.E.,von Koch F.,Conrad U.,Fett W.,Kurzeder C.,Lück H.-J.,Stickeler E.,Urbaczyk H.,Liedtke B.,Salat C.,Harbeck N.,Müller V.,Schmidt M.,Hasmüller S.,Lenhard M.,Schuster T.,Nekljudova V.,Lebeau A.,Loibl S.,von Minckwitz G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/9/1988/13784859/mdq709.pdf

Reference36 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006;Kaufmann;Ann Oncol,2007

2. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update;Kaufmann;J Clin Oncol,2006

3. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group;von Minckwitz;J Clin Oncol,2005

4. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease;Gralow;J Clin Oncol,2008

5. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification;Current Opinion in Oncology;2024-06-13

2. “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”;The Breast;2024-02

3. Selection of breast cancer subtypes to improve benefits of intensive dose‑dense chemotherapy: A systematic meta‑analysis;Oncology Letters;2023-11-07

4. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer;Japanese Journal of Clinical Oncology;2023-08-22

5. Association between event-free survival and overall survival in early-stage triple-negative breast cancer;Future Oncology;2023-08-21